
## Van K Morris

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4746746/publications.pdf Version: 2024-02-01



VAN K MODDIS

#	Article	IF	CITATIONS
1	Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer. New England Journal of Medicine, 2019, 381, 1632-1643.	27.0	918
2	Phase II Pilot Study of Vemurafenib in Patients With Metastatic <i>BRAF</i> -Mutated Colorectal Cancer. Journal of Clinical Oncology, 2015, 33, 4032-4038.	1.6	583
3	Nivolumab for previously treated unresectable metastatic anal cancer (NCl9673): a multicentre, single-arm, phase 2 study. Lancet Oncology, The, 2017, 18, 446-453.	10.7	322
4	Classifying Colorectal Cancer by Tumor Location Rather than Sidedness Highlights a Continuum in Mutation Profiles and Consensus Molecular Subtypes. Clinical Cancer Research, 2018, 24, 1062-1072.	7.0	225
5	ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal–Anal Task Forces whitepaper. Nature Reviews Clinical Oncology, 2020, 17, 757-770.	27.6	218
6	Clinical and molecular characterization of earlyâ€onset colorectal cancer. Cancer, 2019, 125, 2002-2010.	4.1	212
7	Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with <i>BRAF</i> V600E Mutation. Cancer Discovery, 2016, 6, 1352-1365.	9.4	192
8	Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge. Annals of Oncology, 2019, 30, 243-249.	1.2	170
9	Progression-Free Survival Remains Poor Over Sequential Lines of Systemic Therapy in Patients With BRAF-Mutated Colorectal Cancer. Clinical Colorectal Cancer, 2014, 13, 164-171.	2.3	108
10	Association of CpG island methylator phenotype and EREG/AREG methylation and expression in colorectal cancer. British Journal of Cancer, 2016, 114, 1352-1361.	6.4	81
11	Comprehensive Genomic Profiling of Metastatic Squamous Cell Carcinoma of the Anal Canal. Molecular Cancer Research, 2017, 15, 1542-1550.	3.4	59
12	MET amplification in metastatic colorectal cancer: an acquired response to EGFR inhibition, not a <i>de novo</i> phenomenon. Oncotarget, 2016, 7, 54627-54631.	1.8	53
13	Phase I/II study of azacitidine and capecitabine/oxaliplatin (CAPOX) in refractory CIMP-high metastatic colorectal cancer: evaluation of circulating methylated vimentin. Oncotarget, 2016, 7, 67495-67506.	1.8	42
14	Prognostic Implications of Mucinous Differentiation in Metastatic Colorectal Carcinoma Can Be Explained by Distinct Molecular and Clinicopathologic Characteristics. Clinical Colorectal Cancer, 2018, 17, e699-e709.	2.3	34
15	Signet ring cell colorectal cancer: genomic insights into a rare subpopulation of colorectal adenocarcinoma. British Journal of Cancer, 2019, 121, 505-510.	6.4	32
16	BRAF inhibitors in clinical oncology. F1000prime Reports, 2013, 5, 11.	5.9	32
17	Comprehensive Clinical and Molecular Characterization of <i>KRAS</i> <sup>G12C</sup> -Mutant Colorectal Cancer. JCO Precision Oncology, 2021, 5, 613-621.	3.0	31
18	Substrate-induced asymmetry and channel closure revealed by the apoenzyme structure ofMycobacterium tuberculosisphosphopantetheine adenylyltransferase. Protein Science, 2004, 13, 2547-2552.	7.6	29

VAN K MORRIS

#	Article	IF	CITATIONS
19	Clinicopathologic Features Associated With Human Papillomavirus/p16 in Patients With Metastatic Squamous Cell Carcinoma of the Anal Canal. Oncologist, 2015, 20, 1247-1252.	3.7	28
20	Pilot Clinical Trial of Perioperative Durvalumab and Tremelimumab in the Treatment of Resectable Colorectal Cancer Liver Metastases. Clinical Cancer Research, 2021, 27, 3039-3049.	7.0	28
21	Population-based Screening for <i>BRAF</i> V600E in Metastatic Colorectal Cancer Reveals Increased Prevalence and Poor Prognosis. Clinical Cancer Research, 2020, 26, 4599-4605.	7.0	26
22	Clinical utility of circulating cell-free DNA in advanced colorectal cancer. PLoS ONE, 2017, 12, e0183949.	2.5	25
23	Effect of primary colorectal cancer tumor location on survival after pulmonary metastasectomy. Journal of Thoracic and Cardiovascular Surgery, 2021, 162, 296-305.	0.8	22
24	SEVERE THROMBOCYTOPENIA WITH IRON DEFICIENCY ANEMIA. Pediatric Hematology and Oncology, 2010, 27, 413-419.	0.8	21
25	Development and Validation of a Gene Signature Classifier for Consensus Molecular Subtyping of Colorectal Carcinoma in a CLIA-Certified Setting. Clinical Cancer Research, 2021, 27, 120-130.	7.0	21
26	Colorectal cancer mutations are associated with survival and recurrence after pulmonary metastasectomy. Journal of Surgical Oncology, 2019, 120, 729-735.	1.7	20
27	A phase II study of axalimogene filolisbac for patients with previously treated, unresectable, persistent/recurrent loco-regional or metastatic anal cancer. Oncotarget, 2020, 11, 1334-1343.	1.8	18
28	Epidemiology and Molecular-Pathologic Characteristics of CpG Island Methylator Phenotype (CIMP) in Colorectal Cancer. Clinical Colorectal Cancer, 2021, 20, 137-147.e1.	2.3	17
29	Improvements in Clinical Outcomes for <i>BRAFV600E</i> -Mutant Metastatic Colorectal Cancer. Clinical Cancer Research, 2020, 26, 4435-4441.	7.0	17
30	Use of Circulating Cell-Free DNA to Guide Precision Medicine in Patients with Colorectal Cancer. Annual Review of Medicine, 2021, 72, 399-413.	12.2	12
31	Clinical characteristics of colitis induced by taxane-based chemotherapy. Annals of Gastroenterology, 2019, 33, 59-67.	0.6	12
32	Multimodal approach and long-term survival in a patient with recurrent metastatic acinar cell carcinoma of the pancreas: A case report. Pancreatology, 2016, 16, 153-156.	1.1	11
33	Role of Immunotherapy in the Treatment of Squamous Cell Carcinoma of the Anal Canal. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 903-908.	4.9	10
34	The Provocative Roles of Platelets in Liver Disease and Cancer. Frontiers in Oncology, 2021, 11, 643815.	2.8	10
35	Overall Survival in Phase 3 Clinical Trials and the Surveillance, Epidemiology, and End Results Database in Patients With Metastatic Colorectal Cancer, 1986-2016. JAMA Network Open, 2022, 5, e2213588.	5.9	10
36	Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy for Patients with Stage 2A Colon Cancer (COBRA). Annals of Surgical Oncology, 2021, 28, 4095-4097.	1.5	8

VAN K MORRIS

#	Article	IF	CITATIONS
37	Association of PIK3CA mutations (mut) with immune engagement and clinical benefit from immunotherapy in microsatellite stable (MSS) colorectal cancer (CRC) patients (pts) Journal of Clinical Oncology, 2019, 37, 3604-3604.	1.6	8
38	Patient-Reported Bowel and Urinary Function in Long-Term Survivors of Squamous Cell Carcinoma of the Anus Treated With Definitive Intensity Modulated Radiation Therapy And Concurrent Chemotherapy. International Journal of Radiation Oncology Biology Physics, 2022, 114, 78-88.	0.8	8
39	Summary of emerging targets in anal cancer: the case for an immunotherapy based-approach. Journal of Gastrointestinal Oncology, 2016, 7, 721-726.	1.4	7
40	Metastatic Anal Cancer and Novel Agents. Surgical Oncology Clinics of North America, 2017, 26, 133-142.	1.5	7
41	Circulating Tumor DNA in Advanced Anal Cancer: A Blood Biomarker Goes Viral. Clinical Cancer Research, 2019, 25, 2030-2032.	7.0	7
42	Outcomes with anti-EGFR monoclonal antibodies in metastatic and recurrent anal squamous cell carcinoma. Expert Review of Anticancer Therapy, 2020, 20, 901-908.	2.4	7
43	Definitive Intensity-Modulated Chemoradiation for Anal Squamous Cell Carcinoma: Outcomes and Toxicity of 428 Patients Treated at a Single Institution. Oncologist, 2022, 27, 40-47.	3.7	7
44	Rhombohedral crystals ofMycobacterium tuberculosisphosphopantetheine adenylyltransferase. Acta Crystallographica Section D: Biological Crystallography, 2004, 60, 195-196.	2.5	6
45	Microbiome Dynamics During Chemoradiation Therapy for Anal Cancer. International Journal of Radiation Oncology Biology Physics, 2022, 113, 974-984.	0.8	5
46	Systemic Therapy in BRAF V600E-Mutant Metastatic Colorectal Cancer: Recent Advances and Future Strategies. Current Colorectal Cancer Reports, 2019, 15, 53-60.	0.5	4
47	Phase I Study of Ramucirumab Plus Merestinib in Previously Treated Metastatic Colorectal Cancer: Safety, Preliminary Efficacy, and Pharmacokinetic Findings. Oncologist, 2020, 25, e1628-e1639.	3.7	4
48	CEA as a blood-based biomarker in anal cancer. Oncotarget, 2021, 12, 1037-1045.	1.8	4
49	Colorectal cancer during pregnancy or postpartum: Case series and literature review. Obstetric Medicine, 0, , 1753495X2110412.	1.1	4
50	Prognostic impact of lymphopenia and neutrophil-lymphocyte ratio for patients with anal squamous cell carcinoma. Journal of Gastrointestinal Oncology, 2021, 12, 2412-2422.	1.4	4
51	Don't blame the messenger: lessons learned for cancer mRNA vaccines during the COVID-19 pandemic. Nature Reviews Cancer, 2022, 22, 317-318.	28.4	4
52	FOLFOXIRI Versus Doublet Regimens in Right-Sided Metastatic Colorectal Cancer: Focus on Subsequent Therapies and Impact on Overall Survival. Clinical Colorectal Cancer, 2020, 19, 248-255.e6.	2.3	3
53	Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA) Journal of Clinical Oncology, 2020, 38, TPS4121-TPS4121.	1.6	3
54	A systematic review of surrogate endpoints (SEPs) for overall survival (OS) in metastatic colorectal cancer (mCRC) Journal of Clinical Oncology, 2019, 37, e18206-e18206.	1.6	3

VAN K MORRIS

#	Article	IF	CITATIONS
55	Clinical biomarkers in colorectal cancer. Clinical Advances in Hematology and Oncology, 2013, 11, 768-76.	0.3	3
56	Can Circulating Tumor DNA in Early-Stage Colorectal Cancer Be More Than a Prognostic Biomarker?. JAMA Oncology, 2019, 5, 1101.	7.1	2
57	Patient-reported Symptom Outcomes and Microsatellite Instability in Patients With Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2020, 19, 48-56.e2.	2.3	2
58	Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer:NRG-GI005 (COBRA) Journal of Clinical Oncology, 2021, 39, TPS148-TPS148.	1.6	2
59	Bullous pemphigoid secondary to bintrafusp alfa, a bifunctional fusion protein targeting TGF-beta and PD-L1. JAAD Case Reports, 2021, 13, 23-25.	0.8	2
60	Clinical and pathologic features correlated with rare favorable survival in patients with BRAFV600E mutated colorectal cancer. Journal of Gastrointestinal Oncology, 2022, 13, 647-656.	1.4	2
61	Anal cancer treatment regimen considerations for the COVID-19 era: In regard to Tchelebi et al. Radiotherapy and Oncology, 2020, 151, 56-57.	0.6	1
62	Bevacizumab Does Not Influence the Efficacy of Partial Splenic Embolization in the Management of Chemotherapy-Induced Hypersplenism. Clinical Colorectal Cancer, 2020, 19, e189-e199.	2.3	1
63	High mutational concordance between primary colorectal tumors and associated pulmonary metastases. Journal of Surgical Oncology, 2020, 121, 984-989.	1.7	1
64	Reply from author: Biology is king, but metastasectomy still has a role for properly selected patients. Journal of Thoracic and Cardiovascular Surgery, 2021, 162, e136-e138.	0.8	1
65	Using circulating tumor DNA for colon cancer adjuvant therapy: to be or not to be?. Clinical Cancer Research, 2021, , clincanres.3564.2021.	7.0	1
66	Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA) Journal of Clinical Oncology, 2022, 40, TPS233-TPS233.	1.6	1
67	BRAF Mutations in Non-Metastatic Colorectal Cancer: Current Relevance and Future Implications. Current Colorectal Cancer Reports, 2015, 11, 303-310.	0.5	0
68	Benchmarking Outcomes for Definitive Treatment of Young-Onset, Locally Advanced Rectal Cancer. Clinical Colorectal Cancer, 2021, , .	2.3	0
69	FOLFOXIRI versus doublet-regimens in the first-line therapy of MSI-S right-sided (RS) metastatic colorectal cancer (mCRC): A survival analysis Journal of Clinical Oncology, 2019, 37, e15060-e15060.	1.6	0
70	Identifying anti-EGFR (EGFRi) response subgroups using evidence of ctDNA selective pressure Journal of Clinical Oncology, 2019, 37, 3587-3587.	1.6	0
71	Meat consumption and BRAF mutation status in colorectal cancer Journal of Clinical Oncology, 2019, 37, e15135-e15135.	1.6	0